A recent Scientific American article highlighting research from Trinity College Dublin has brought attention to blood-brain barrier disruption in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE), providing clinical evidence that supports the potential application of Sigyn Therapeutics' CardioDialysis technology for treating neuroinflammatory diseases. The article, published on March 21 and titled "Brain's Protective Barrier Stays Leaky for Years after Playing Contact Sports," coincides with a study in Science Translational Medicine reporting that the blood-brain barrier may remain compromised for decades after athletes retire from sports involving repetitive head trauma.
When the blood-brain barrier's integrity is compromised, inflammatory molecules and pathogenic toxins from the bloodstream can enter the brain, triggering neuroinflammation that can lead to abnormal tau protein accumulation—a hallmark of CTE. Researchers observed that former athletes in the study appeared to exist in a state of chronic hyperinflammation. This finding adds to growing evidence that systemic inflammation in the bloodstream is a key driver of neuroinflammation associated with progressive disorders like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
Given its broad-spectrum mechanism for clearing inflammatory and pathogenic molecules from blood, CardioDialysis is positioned as a potential adjunct therapy for such neuroinflammatory conditions. Sigyn Therapeutics CEO Jim Joyce stated that CardioDialysis may play a meaningful role in slowing neuroinflammatory disorder progression, particularly in high-risk individuals or early disease stages, by reducing inflammatory and pathogenic factors to help stabilize the blood-brain barrier. The Scientific American article can be accessed at https://www.scientificamerican.com/article/brains-protective-barrier-stays-leaky-for-years-after-playing-contact-sports/.
Sigyn Therapeutics is pursuing a strategic transaction focused on using CardioDialysis to reduce systemic inflammation linked to traumatic brain injury, though its lead clinical indication remains cardiovascular disease—the world's leading cause of death. In cardiovascular treatment, CardioDialysis aims to reduce inflammatory mediators and cholesterol-transporting lipoproteins to prevent heart attacks, strokes, and other major adverse cardiovascular events, overcoming limitations of single-target drugs. The technology's underlying mechanism is also being explored for sepsis, life-threatening viral infections, and neurological disorders associated with systemic inflammation.
The implications of this research and Sigyn's technology are significant for public health, particularly for athletes, military personnel, and aging populations susceptible to neuroinflammatory diseases. By addressing systemic inflammation that compromises the blood-brain barrier, CardioDialysis could potentially slow disease progression in conditions currently lacking curative treatments, offering a novel approach in the emerging field of subtractive medicine. This development highlights the interconnectedness of cardiovascular and neurological health, suggesting that therapies targeting bloodstream inflammation may have broad applications across multiple disease states.
